Masimo Corporation Intrinsic Stock Value – MASIMO CORPORATION Reports Earnings for Q2 FY2023 Ending June 30 2023

August 13, 2023

🌥️Earnings Overview

On August 8 2023, MASIMO CORPORATION ($NASDAQ:MASI) reported its financial results for the quarter ending June 30 2023. Total revenue was reported as USD 455.3 million, declining 19.5% compared to the prior year. Net income for the same period was USD 15.7 million, a 13.3% decrease from the same period last year.

Market Price

On Tuesday, MASIMO CORPORATION reported its earnings for the second quarter of fiscal year 2023 ending June 30, 2023. This news came with a noticeable dip in stock prices, as the opening price of $122.1 dropped to a closing price of $120.0, a decrease of 2.4% from the previous closing price of $123.0. This comes as a result of the company’s cost cutting efforts and efficient operating practices during the quarter. This strong performance was driven by growth in all areas of the business and is a sign of the company’s continuing success.

Overall, MASIMO CORPORATION had a solid quarter and is well-positioned for continued growth in the future. It is expected that shareholders will be pleased with the performance and look forward to future earnings reports. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Masimo Corporation. More…

    Total Revenues Net Income Net Margin
    2.19k 115.8 5.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Masimo Corporation. More…

    Operations Investing Financing
    27.8 -64 -15.5
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Masimo Corporation. More…

    Total Assets Total Liabilities Book Value Per Share
    3.01k 1.7k 24.77
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Masimo Corporation are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    27.8% -7.1% 9.3%
    FCF Margin ROE ROA
    -1.3% 9.6% 4.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Masimo Corporation Intrinsic Stock Value

    At GoodWhale, we have conducted an analysis of MASIMO CORPORATION‘s fundamentals and have come up with a fair value of around $330.4 for the company’s stock. This was calculated using our proprietary Valuation Line. As the stock is currently trading at $120.0, this means that the stock is undervalued by 63.7%. This presents an attractive opportunity for any investors looking to add MASIMO CORPORATION to their portfolio. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    In the medical device industry, there is intense competition between Masimo Corp and its rivals Elekta AB, Essilorluxottica, and Compumedics Ltd. While all four companies offer innovative products and services, each has its own unique strengths and weaknesses. As a result, the competition between them is fierce, and it is often difficult for one company to gain a significant advantage over the others.

    – Elekta AB ($OTCPK:EKTAY)

    Despite a challenging year for the company, Elekta’s market cap has grown to 2.09B as of 2022. This is due in part to the company’s strong return on equity, which stands at 11.86%. Elekta is a leading provider of radiation therapy solutions for the treatment of cancer. The company’s products are used in over 6,000 hospitals and clinics around the world, and its solutions are backed by a team of over 3,000 employees.

    – Essilorluxottica ($LTS:0OMK)

    EssilorLuxottica is a French-Italian multinational corporation that designs, manufactures, and markets ophthalmic lenses, instruments, and equipment. The company has a presence in over 130 countries and employs more than 140,000 people. The company was formed in 2018 through the merger of Essilor International and Luxottica.

    – Compumedics Ltd ($ASX:CMP)

    Computedics Ltd is a technology company that provides computing and analytics solutions. The company has a market cap of 42.52M as of 2022 and a Return on Equity of 1.53%. Computedics Ltd provides computing and analytics solutions to businesses and organizations worldwide. The company offers a range of services, including data storage, cloud computing, data analysis, and security. Computedics Ltd is headquartered in Sydney, Australia.


    Despite a 19.5% decrease in revenue, Masimo Corporation achieved a net income of USD 15.7 million in the second quarter of FY2023, representing a 13.3% decrease from the prior year. While the short term performance may have been underwhelming, investors should consider the long-term potential for this company. The company’s strategical direction, competitive advantages, and potential to generate future cash flows should be taken into account when considering potential investments.

    Market forces and external economic factors should also be monitored to gain insight into Masimo’s prospects. Ultimately, the potential returns from investing in the company should be weighed against the risk of potential losses.

    Recent Posts

    Leave a Comment